NCT04303117View on ClinicalTrials.gov

NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions
Kaposi Sarcoma
Interventions
DRUG

NHS-IL12

An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.

DRUG

M7824

1200 mg administered IV every two weeks while on NHS-IL12.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH